Acelity L.P. Inc., a leading global medical technology company headquartered in the United States, specialises in advanced wound care and regenerative medicine. Founded in 1976, Acelity has established itself as a pioneer in the industry, focusing on innovative solutions that enhance patient outcomes. With a strong presence in North America, Europe, and Asia-Pacific, the company offers a diverse range of products, including advanced wound dressings and biologics. Acelity's unique offerings, such as the KCI brand of negative pressure wound therapy, set it apart in the competitive landscape. The company has achieved significant milestones, including numerous patents and awards for its cutting-edge technologies. As a trusted partner in healthcare, Acelity continues to lead the way in transforming wound care and improving the quality of life for patients worldwide.
How does Acelity L.P. Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Acelity L.P. Inc.'s score of 17 is lower than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Acelity L.P. Inc., headquartered in the US, currently does not have available carbon emissions data for the most recent year, nor does it report any specific reduction targets or climate commitments. The absence of emissions data suggests that the company may not have publicly disclosed its carbon footprint or related initiatives. Additionally, there are no climate pledges or commitments to science-based targets (SBTi) reported, indicating a potential gap in their climate strategy. As Acelity operates within the medical technology sector, it is essential for the company to consider industry standards for emissions reporting and reduction. The lack of disclosed emissions data and targets may impact its reputation and alignment with global sustainability goals. Without specific initiatives or commitments, Acelity's approach to climate action remains unclear.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Acelity L.P. Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
